All Cancers. One Solution.

SMART-Phage™ for Truly Tumor-Specific Antibody Discovery

Partnering with biopharma to deliver tailored antibody solutions that drive therapeutic progress

All cancers have one thing in common -

a modification abundant in cancers but absent in healthy cells.

“Sucess starts with the right target” KOL

Healthy tissue

Tumor tissue

Combotopes' proprietary SMART-Phage™ Antibody Discovery Platform generates antibodies with:

Tumor specificity

High affinity

Flexibility

Why does it matter?

For Pharma:

  • Novel cancer targets

  • ADC, BsAb, BiTE, RIT, CART

  • Untouched IP space

For Patients:

  • Better treatment options

  • Reduced side-effects

  • Improved quality of life

What we deliever

Antibodies for truly cancer-specific antigens with fast, cost-effective discovery and collaborative IP solutions

EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN

〰️

EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN 〰️

We offer an attractive win-win partnership business model

  • Upfront, and milestone payments tied to development and regulatory achievements

  • Minimum royalties and royalties based on product sales.

Crystal structure revealing how Combotope antibodies specifically binds cancer-specific Tn-glycoprotein epitopes

Leadership

  • Dr. Klas Ola Blixt

    CO-FOUNDER, INVENTOR, & CEO

    Ola invented the SMART-Phage technology and is an expert in aberrant glycosylation for cancer-specific antibody development. With 20+ years in chemical biology and antibodies, he has an H-index of 50, multiple patents, and 15+ years of management experience.

  • Dr. Søren Nyboe Jakobsen

    CO-FOUNDER, CSO

    Søren is an inventor of key patents in molecular display and immune cell detection. He founded Tetramer Shop (acquired by 10x Genomics) and has led innovation at firms like Novo Nordisk, Nuevolution, and Immudex, with strong biotech startup leadership experience.

Combotope Therapeutics ApS

Diplomvej 381

DK-2800 Kongens Lyngby

Denmark

Contact:

olablixt@combotope.com

Company registration (CVR) no. 44308266